Our Research Approach
We are building Hemab to re-imagine care for people living with bleeding disorders whose individual needs were overlooked by healthcare. By leveraging key insights into the biology of clotting, we are harnessing the biotechnological revolution to develop targeted therapies for underserved bleeding and thrombotic disorders like Glanzmann Thrombasthenia, FVII Deficiency, Von Willebrand Disease, and others.
Every Hemab program begins by listening to people who live with their conditions and learning about what they still need.
Lived experiences reveal bleeding patterns, treatment challenges, and daily impacts invisible to conventional research.
Our therapeutic candidates are designed to connect with the body’s natural clotting proteins in a very precise way. This helps protect them from breaking down and lets them build up to levels that can help stop bleeding. In some cases, the treatment keeps the protein active; in others, it turns it off, giving us the flexibility to treat different clotting problems. When needed, our technology can also help guide these proteins to the site of an injury to support healing.
Our strategic guidance, Hemab 1-2-5TM is targeting development of five development projects by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, active lives.
Time to leapfrop therapeutics is now.
Our strategic Hemab 1-2-5™ roadmap represents our commitment: advancing five development projects by 2025 that fundamentally transform care for these long-neglected conditions. We envision a future where people with these disorders can live without constantly planning around their next bleed—a future where prevention, not just management, becomes the standard of care.
Decades of Treatment Neglect.
For decades, certain bleeding disorders have remained in the shadows as research and innovation focused elsewhere.
At Hemab, we exist specifically for people with conditions like Glanzmann Thrombasthenia, FVII Deficiency, and von Willebrand Disease—conditions where treatment options have changed little despite scientific advances elsewhere.
Overlooked voices, unmet needs
Every Hemab program starts with the experts who understand these conditions most intimately—the people living with them every day.
These conversations reveal what clinical literature often misses: the anxiety of unpredictable bleeding, the careful planning required for everyday activities, and the nuanced impact these conditions have on daily life that may not be fully captured in standard clinical assessments.
Harnessing new possibilities in therapeutics.
Our therapeutic approach works in harmony with the body's natural clotting processes. We remain technology-agnostic, selecting the optimal scientific approach for each specific condition.
This allows us to develop treatments that can:
• Shield essential clotting proteins from premature breakdown
• Enable these proteins to accumulate to levels that prevent bleeding
• Precisely control activation or deactivation within the clotting cascade
• Direct these proteins to injury sites where they're needed most
This precision allows us to address different bleeding conditions with targeted solutions rather than generic approaches.
Pipeline
Hemab unites experts in clotting, patient care, and drug development to transform the lives of people with bleeding disorders
Programs
Sutacimig is a bispecific antibody designed to mimic the function of factor VIIa while targeting activated platelets at the site of bleeding. This novel approach aims to provide prophylactic protection for patients with Glanzmann Thrombasthenia—a condition discovered over a century ago that still lacks dedicated preventative treatments.
The Phase 2 study of Sutacimig is now fully enrolled, with patients receiving prophylactic treatment designed to prevent bleeding events. Initial data indicates promise for a preventative approach to GT management.
HMB-002 is a monovalent antibody designed to accumulate endogenous von Willebrand Factor as a prophylactic treatment option to prevent and reduce frequency of bleeding events in people with von Willebrand Disease (VWD).
Our VWD 360 and VELORA Discover programs are mapping the real-world experience of living with VWD, documenting bleeding patterns, treatment limitations, and quality of life impacts that often go unrecognized in clinical literature.
The VELORA Pioneer Phase 1/2 study is now enrolling patients with VWD. This study will evaluate the safety, tolerability, and early efficacy signals of HMB-002 as a preventative therapy.
The VELORA Discover and Pioneer programs are actively enrolling.
Future Pipeline Development
Our technology platform and patient-focused approach positions us to expand into additional overlooked bleeding and thrombotic disorders. We're committed to our Hemab 1-2-5™ strategy: developing five development projects by 2025 to transform treatment where innovation has been limited.
Looking Beyond the Horizon: We're actively researching additional conditions where our approach could address significant unmet needs.
If you have questions about our ongoing clinical trials, please get in touch with our Medical team
Meet the Team
Hemab unites experts in clotting, patient care, and drug development to transform the lives of people with bleeding disorders
Latest News
